Second Amendment to Development and Supply Agreement



 Exhibit 10.4 
 Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete
version of this exhibit has been filed separately with the Securities and Exchange Commission. 
 [***] 

SECOND AMENDMENT 
 TO DEVELOPMENT AND SUPPLY AGREEMENT 
 Effective as of
date of the last signature below, Abbott Laboratories, an Illinois corporation having a principal place of business at 100 Abbott Park Road, Abbott Park, Illinois 60064-3500 (“Abbott”), and Seattle Genetics, Inc., a Delaware corporation
having a principal place of business at 21823 – 30th
Drive Southeast in Bothell, Washington 98021 (“Seattle Genetics”) (individually the “Party” or collectively the “Parties”) agree to the following terms and conditions (“Second Amendment”) as set forth below.

 WHEREAS, the Parties entered into a Development and Supply Agreement with an Effective Date of February 23, 2004
for the manufacture of a chimeric anti-CD30 AC10 monoclonal antibody known as cAC10 Bulk Drug Substance, which also constitutes the antibody component of SGN-35 (the “Agreement”); and 

WHEREAS, the Parties have agreed to conduct additional development and manufacturing work pursuant to the terms and conditions of
the Agreement; and 
 NOW, THEREFORE, in consideration of the mutual covenants and agreements contained here and for
other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows: 
 1. Incorporation of the Agreement. All capitalized terms which are used but not otherwise defined herein shall have the same meanings as set forth in the Agreement, and the Agreement, to the extent
not inconsistent with this Second Amendment, is incorporated herein by this reference as though the same was set forth in its entirety. To the extent any terms and provisions of the Agreement are inconsistent with the amendments set forth in
Paragraphs 2 and 3 below, such terms and provisions shall be deemed superseded hereby. Except as specifically set forth herein, the Agreement shall remain in full force and effect and its provisions shall be binding on the parties. 

2. Process Development Work. The Parties agree that Abbott shall perform the activities set forth in Stages 5, 6, 7 and 8 of
Attachment 1 hereto pursuant to the terms and conditions of the Agreement. 
 3. Additional Clinical Supplies. The
Parties agree that Abbott shall manufacture and Seattle Genetics shall purchase [***] additional batches of [***] as described in Stage 7 of Attachment 1 hereto in accordance with the terms and conditions of the Agreement, including the Bulk Drug
Substance Specifications set forth therein; provided that the total price for all [***] batches shall be [***], (the “[***]”) [***]. Abbott shall initiate billing and will continue in accordance with the Payment Schedule attached
hereto and Seattle Genetics shall [***] regardless of whether the Agreement subsequently expires or terminates, except in the case of Abbott’s breach of the Agreement or non-performance under this Second Amendment. Stage 7 billings may be
combined on the same invoice with other, regular Payment Schedule charges. Abbott shall [***] for these additional five (5) batches in [***] beginning on [***] (the “[***]”.) Manufacture of the first batch will begin no sooner
than [***] and manufacture of the first [***] will begin no sooner than [***] after the [***]. 
 4. [***] and Payment
Schedule. As compensation for the activities to be performed by Abbott pursuant to Attachment 1 hereto, Seattle Genetics shall pay to Abbott the price established for 







 
each project stage in Attachment 1, on the dates set forth in Attachment 2. [***] prior to the [***], Seattle Genetics agrees to make a binding commitment to pay the [***], [***] at the
percentages and upon achievement of the milestones as follows, [***], [***] and [***]. As of the [***], Abbott shall be [***] regardless of whether this Agreement subsequently expires or terminates, with [***], except in the case of Abbott’s
breach of the Agreement or non-performance under this Second Amendment. 
 5. Project References. All references to the
Project set forth in the Agreement, with the exception of the Payment Schedule and [***] for the Project, shall also be deemed to apply to the activities performed by Abbott, pursuant to this Second Amendment. 

6. Effectuation. The amendment to the Agreement contemplated by this Second Amendment shall be deemed effective as of the last
date written below upon the full execution of this Second Amendment and without any further action required by the parties hereto. There are no conditions precedent or subsequent to the effectiveness of this Second Amendment. All terms and
conditions set forth in Agreement that are not amended hereby shall remain in full force and effect. Any term of this Second Amendment may be amended with the written consent of both parties. From the date hereof, any reference to the Agreement
shall be deemed to refer to the Agreement as amended by this Second Amendment. 
 7. Counterparts. This Second Amendment
may be executed in two or more counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument. One or more counterparts of this Second Amendment may be delivered by facsimile,
with the intention that delivery by such means shall have the same effect as delivery of an original counterpart thereof. 
 8.
Entire Agreement. This Second Amendment and exhibits hereto are the product of both of the parties hereto, and together with the Agreement and exhibits thereto constitute the entire agreement between such parties pertaining to the subject
matter hereof, and merge all prior negotiations and drafts of the parties with regard to the transactions contemplated herein. 

IN WITNESS WHEREOF, the parties have executed this Second Amendment as of the dates set forth below. 

 

									
	ABBOTT LABORATORIES	 		 	SEATTLE GENETICS, INC.
					
	By:	 	 /s/ Mike L. McGibbon
	 		 	By:	 	 /s/ Clay B. Siegall

					
	Name:	 	 Mike L. McGibbon
	 		 	Name:	 	 Clay B. Siegall

					
	Title:	 	 General Manager, Commercial Operations
	 		 	Title:	 	 President & CEO

					
	Date:	 	 6/15/2009
	 		 	Date:	 	 6/05/2009


 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions. 

  

					
	11/3/2011	  	2	  	CONFIDENTIAL









 ATTACHMENT 1 
 PROJECT SCOPE 
 [***] 

[***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 







 ATTACHMENT 1 
 PROJECT SCOPE 
 [***] 

[***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 







 ATTACHMENT 1 
 PROJECT SCOPE 
 [***] 

[***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 







 ATTACHMENT 2 
 PAYMENT SCHEDULE 
 [***] 

[***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.